Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone

The proteasome inhibitor carfilzomib is highly effective in the treatment of multiple myeloma. It irreversibly binds the chymotrypsin-like active site in the β5 subunit of the 20S proteasome. Despite impressive response rates when carfilzomib is used in combination with immunomodulatory agents in ne...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Leuk Lymphoma
Huvudupphovsmän: Manasanch, Elisabet E., de Larrea, Carlos Fernández, Zingone, Adriana, Steinberg, Seth M., Kwok, Mary, Tageja, Nishant, Bhutani, Manisha, Kazandjian, Dickran, Roschewski, Mark, Wu, Peter, Carter, George, Zuchlinski, Diamond, Mulquin, Marcia, Lamping, Liz, Costello, Rene, Burton, Deborah, Gil, Lindsay A., Figg, William D., Maric, Irina, Calvo, Katherine R., Yuan, Constance, Stetler-Stevenson, Maryalice, Korde, Neha, Landgren, Ola
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2016
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6357961/
https://ncbi.nlm.nih.gov/pubmed/27687480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2016.1214953
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk